Personalized and Tumor Informed Circulating Tumor DNA Assay for Molecular Residual Disease Monitoring of Solid Malignancies.

ABSTRACT: Emerging evidence suggests that minimal residual disease (MRD) monitoring in solid tumors has implications for prognosis, treatment response, and therapeutic intervention. However, detecting MRD requires highly sensitive and specific circulating tumor DNA (ctDNA) assays. Therefore, we developed an innovative MRD monitoring assay that offers superior performance and cost advantage. Our approach utilizes a comprehensive genomic profiling panel to characterize the patient-specific mutational landscape of tumor tissue and selects up to 20 top-ranked variants to design a personalized panel, which is integrated with a tumor-naive cancer-type-specific fixed panel for ultra-deep sequencing of plasma ctDNA to monitor MRD in common solid tumors. Its limit of detection at the sample level reaches as

SUBMITTER: Liu L 

PROVIDER: S-EPMC12674089 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature